2022
DOI: 10.1002/cpdd.1197
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ‐73763989 in Healthy Chinese Adult Participants

Abstract: JNJ‐73763989, composed of the 2 short‐interfering RNA triggers JNJ‐73763976 and JNJ‐73763924, targets all hepatitis B virus messenger RNAs, thereby reducing all viral proteins. In this phase 1, single‐site, open‐label, parallel‐group, randomized study, participants were given 1 subcutaneous injection of JNJ‐73763989 (100 or 200 mg) to investigate the pharmacokinetics, safety, and tolerability of JNJ‐73763989 in healthy Chinese adult participants. Plasma and urine pharmacokinetic parameters were determined for … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
0
0

Year Published

2024
2024
2025
2025

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 11 publications
0
0
0
Order By: Relevance
“…JNJ-73753989 (JNJ-3989, formerly ARO-HBV): JNJ-3989 is composed of two siRNAs which target both the S gene and X gene of the HBV. Consequently, it impairs the production of HBV RNA transcripts which are essential for replication[ 47 ].…”
Section: Future Therapy For Hepatitis Bmentioning
confidence: 99%
“…JNJ-73753989 (JNJ-3989, formerly ARO-HBV): JNJ-3989 is composed of two siRNAs which target both the S gene and X gene of the HBV. Consequently, it impairs the production of HBV RNA transcripts which are essential for replication[ 47 ].…”
Section: Future Therapy For Hepatitis Bmentioning
confidence: 99%